265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
James G. Krueger, Sandra Garcet, J. Cheng, Sanjay Kumar, Jie Tang, John Blau, Yan Zhao, Weidong Zhang, Bhaskar Saha, V. Arunachalam, G.A. Heap, Paresh Thakker, Anindo Choudhury
We don't know much about this study yet.
We're maintaining the world's largest resposity of hair loss
research. You can help out the community by
sending a PDF of this study here
.
Not sure how to get a study's PDF? You can email the authors
of the study.
